Pfizer Inc

• Tempus AI experienced strong buying momentum and pronounced intraday price volatility. • CEO Eric Lefkofsky presented a compelling revenue growth outlook at conference. • The company reported an annual revenue of $1.27B and net profit of $-245.03M.

• Arrowhead shares dropped despite positive Phase 1/2a data for ARO-DIMER-PA due to profit-taking. • The company reported annual revenue of $829.45M with a net loss of $1.63M. • Technical indicators show a MACD sell signal and an RSI of 27.985.

• Ascendis Pharma stock fell after terminating its collaboration agreement with Novo Nordisk. • Investors worry about independent funding and high expenses for obesity clinical programs. • The company reported an annual revenue of $854.80M and net loss.

• Eli Lilly management highlighted core metabolic therapies and late-stage pipeline updates. • The company reported $65.18 billion in annual revenue and strong net profits. • Analysts maintain Buy ratings with an average price target of $1300.31.

• Novartis shares dropped after the Phase III HARBOR trial for del-desiran failed. • The pelacarsen cardiovascular trial also missed its primary endpoint of reducing events. • Multiple pipeline setbacks intensified investor scrutiny and raised structural growth risks.

• McKesson agreed to acquire Precision Medicine Group to expand its oncology portfolio. • The company raised its quarterly dividend payout by fifteen percent. • Annual revenue reached $403.43 billion, ranking first in the industry.